The reference-standard
market, measured.
A data-led audit of the U.S. research peptide catalog: 50 suppliers, 10 scoring criteria, a documentation rubric, supplier-origin analysis, and a twelve-month forward forecast.
What's in the Q2 report.
Seven chapters, one appendix. Written for research chemists and procurement leads at U.S. laboratories, clinics, and academic groups.
The U.S. research peptide market is consolidating on documentation discipline.
The post-Peptide-Sciences vacuum created roughly 18 months of supplier shuffling. As of Q2 2026, the market is stratifying into two tiers: catalogs with rigorous per-lot documentation and catalogs without. The former is taking share.
This is the first of a quarterly independent audit. Unlike the industry reports currently circulating, largely self-promotional pieces from suppliers ranking themselves first, this edition is built around three commitments: methodological disclosure, independent HPLC re-testing, and naming names, positive and negative.
What the data shows: a small number of catalogs have matured into credible research-grade suppliers. A larger number are drifting into consumer framing that has historically preceded category-exit events, the same trajectory Peptide Sciences followed before its closure.
Chemistry quality is converging. Documentation quality isn't. That gap is the 2026 supplier-selection signal.
The four most consequential findings: (1) BPC-157 search volume remains dominant at roughly 165K per month with GHK-Cu up +1,016% year over year, driven by skincare crossover; (2) 7 of 50 audited suppliers fail basic COA rigor on release parameters we consider non-negotiable; (3) price volatility on GH-axis SKUs has normalized but GLP-family compounds are +34% since Q3 2025; (4) three mid-tier catalogs are showing early indicators that match the 12-month pre-exit pattern.
The catalog landscape.
We audited 50 U.S.-facing peptide suppliers on ten weighted criteria: synthesis location, COA batch-specificity, HPLC method disclosure, MS confirmation, endotoxin testing, counterion quantitation, SKU stability, reorder consistency, compliance framing, and ownership transparency. The resulting top-10 is below. Position 1 is BioFusion Aminos for the reasons enumerated in methodology; this report was prepared in-house and that conflict is disclosed explicitly.
Position 1 of this ranking is the author. That bias is disclosed explicitly, and the methodology appendix provides the raw scorecards so any reader can recompute the ranking with their own weights.
Methodology Note, BioFusion Research Q2 2026The documentation, weighed.
A reference-grade Certificate of Analysis is a release record, not a marketing artifact. This chapter introduces the COA scoring rubric we applied across the 50-supplier audit, and surfaces the dimensions where the category is currently weakest.
The gap between the two ends of the COA rubric, 88% of suppliers disclose an HPLC method but only 18% publish the COA pre-purchase, is the single clearest signal of where the market is going to differentiate in 2026.
COA Rubric Finding, BioFusion Research Q2 2026The origin question.
"American-manufactured" is a term used liberally across the research-peptide market. Applying a narrower definition, where the Fmoc synthesis actually happens, not where the package ships from, the claim holds less often than search results imply. This chapter maps what the 50-supplier audit looks like when the origin question is asked honestly.
Thirty-four percent of audited suppliers perform Fmoc synthesis on U.S. equipment. Forty percent ship from U.S. warehouses but source bulk powder overseas; the "domestic" claim holds only at the packaging step, not the chemistry step. Fourteen percent do not disclose the synthesis location at all, which for research-grade reference materials should be treated as a documentation failure rather than a privacy courtesy.
The solid-phase peptide synthesis happens in a U.S. facility. Couplings, deprotections, and resin cleavages are performed domestically. This is the definition a research chemist should apply when evaluating origin.
Bulk powder is synthesized overseas, typically in Asia, and shipped to a U.S. warehouse. The U.S. operation aliquots, labels, and ships. The COA may be passed through from the overseas manufacturer or re-issued with the U.S. supplier's logo on top.
Chain-of-custody gaps introduce exactly the variance that research reproducibility depends on eliminating. Two vials of identical label can originate from different synthesis runs, by different manufacturers, under different documentation standards.
For research labs, the one question that separates the catalog tiers is: where, exactly, is the peptide synthesized? If the answer is not a specific U.S. address, the next question is why.
Chapter Three, Supply-Chain OriginsWhere the demand is moving.
BPC-157 remains the category head term. The interesting signals for 2026 are below it, where GHK-Cu's skincare crossover, GLP-family triple-receptor interest, and mitochondrial peptide chemistry are creating previously non-existent search volume.
BPC-157, TB-500, and the GH-axis triad (CJC-1295, Ipamorelin, Tesamorelin) still dominate commercial-intent queries. Head-term volume is stable but SERP competition is highest here; the 2026 win is not in outranking the head, but in owning the long-tail around it.
GHK-Cu is the breakout compound of the year, driven almost entirely by a skincare crossover. MOTS-c tracks behind it with a different audience, mitochondrial-biology researchers, not consumer beauty. Triple-receptor GLP agonists are the institutional-research growth term.
Nearly half of research-peptide search volume is informational: "what is BPC-157," "HPLC purity meaning," "how to read a COA." The commercial and transactional tiers together represent roughly 38% of query volume, the segment where research labs make actual supplier decisions. The intent split itself is stable across quarters; what changes is where that volume is directed.
For research labs, the practical reading of this chart is: start your supplier evaluation at the informational tier. How a catalog answers a chemistry question is a faster signal of documentation rigor than how it prices a product.
Keyword & SERP Analysis, Q2 2026The compliance cliff.
Peptide Sciences did not close because the chemistry failed. It closed because the marketing, framing, and audience drift caught up with the compliance infrastructure. Three mid-tier catalogs are currently showing the same twelve-month trajectory. This chapter isolates the four observable signals.
When a catalog shifts from "research peptide" to "peptide for recovery / healing / hair growth," the audience shifts with it. Payment processors and search platforms re-classify the site within quarters, not years. Once classified as consumer-health, the site has 12 to 18 months of runway before platform churn begins.
Review widgets, star-rating schema, and "verified purchaser" testimonials below product cards are the most common transgression. They drive conversion short-term but signal human-use context to processors and regulators, the exact signal that triggered historical enforcement.
Recurring "subscribe & save" models on research peptides assume repeat consumption. That assumption is inappropriate for reference-standard research use and attracts classifier flags on card networks. Annual memberships (discount-based, not auto-ship) avoid this.
When a supplier's current domain is under 18 months old and redirects from a recently-defunct predecessor, that is the downstream effect of a processor ban. Research labs evaluating a supplier should check WHOIS registration dates and archive history before committing a standing reorder.
Six catalogs in the audit (12% of 50) exhibit all four cliff signals simultaneously. Based on the Peptide Sciences timeline, these are the suppliers most likely to face processor, platform, or enforcement disruption in the next 12 to 18 months. Research labs with standing reorder patterns against these catalogs should have a documented backup supplier identified now.
The next twelve months.
Six directional calls for Q3 2026 through Q2 2027. Not predictions, these are the structural shifts already visible in the data above, projected forward with the assumptions each rests on made explicit.
By Q2 2027, per-lot pre-purchase COAs will be considered baseline, not premium. Catalogs without them will be priced out of procurement contracts. Watch for a 15 to 20% share migration from generic-COA suppliers to published-COA suppliers.
Copper peptide demand will continue pulling suppliers toward skincare-adjacent framing. Research-only catalogs that hold the compliance line will capture institutional demand; catalogs that drift will capture consumer demand with the associated processor exposure.
Based on the four-signal compliance cliff in Chapter 5, at least one current top-10 supplier will face a processor, platform, or enforcement disruption sufficient to force a rebrand, domain change, or exit. Research labs on standing reorders should have backup suppliers pre-qualified.
Generalist catalogs will narrow. Expect several mid-tier suppliers to pare their SKU counts and focus on one or two peptide classes (GLP, GH-axis, copper complexes) where they can hold a documentation and chemistry-quality advantage. Breadth-based competition loses to depth-based competition.
Overseas manufacturers are beginning to issue batch-specific COAs that match U.S. documentation standards. The "American-manufactured" premium narrows over the next four quarters on documentation grounds. Chain-of-custody and response-time differences remain the durable U.S. advantages.
Academic, clinical, and independent-lab buyers will increasingly concentrate reorders on a smaller set of documented suppliers. Expect 60 to 70% of institutional volume to consolidate into three to five catalogs within the year as procurement teams formalize supplier qualification.
What we learned putting this together.
The first edition of an industry audit is always as much about methodology as it is about findings. Three reflections on what the data across these six chapters adds up to, and what labs, suppliers, and observers of the category should take into the next quarter.
First, the U.S. peptide research-standard category is more stable than its surface makes it look. The post-Peptide-Sciences shuffling produced noise, price spikes, grey-market expansion, short-lived catalogs, but the underlying chemistry supply chain held. Every compound that was available in Q2 2024 is available in Q2 2026, synthesized domestically, documented per-lot, and shipped from U.S. inventory. The category is not in crisis; it is in transition.
Second, the winners of the next 18 months will be the suppliers who hold documentation discipline while everybody else drifts. The temptation to cross into consumer framing is real; the revenue upside is real; the compliance downside is also real. Peptide Sciences is the category's most recent reminder that short-term revenue and long-term survival are sometimes in tension.
The category is not short on chemistry. It is short on suppliers willing to publish what they test, how they test, and what the result was.
Third, the basis for a supplier relationship is shifting from price to paper trail. Research labs making standing-reorder decisions in 2026 are asking a different set of questions than they asked in 2022: not "what does this cost per milligram," but "where is the synthesis address, what is on the COA, and what happens if a lot fails internal verification." The catalogs that answer those questions clearly win the recurring research dollars. The catalogs that deflect them lose those dollars quietly, one lab at a time.
We will publish Q3 2026 in early August. The same methodology, the same rubric, the same audit universe. We will revisit every directional call in Chapter 6 with a scorecard of what held and what did not. The goal of this publication is not to advocate for any particular supplier; it is to give research labs a defensible vocabulary for evaluating the category and a reason to expect more from it.
The next edition is the interesting one. Q2 2026 is the baseline. Q3 2026 is where the forecast meets the data. We will hold ourselves to the same standards we hold everyone else to.
BioFusion Research, Q2 2026 Closing NoteCatalog cross-reference
The compounds tracked in this Q2 2026 report map to specific reference standards in the BioFusion catalog. Browse them by class:
Further reading from the BioFusion Reference Library
- The Post-Peptide-Sciences Landscape: Where Research Labs Are Sourcing Now
- Choosing a U.S. Peptide Supplier: A 2026 Research Chemistry Checklist
- Why American Manufacturing Matters for Peptide Reference Standards
- How to Read a Peptide Certificate of Analysis
- Understanding HPLC Purity: Reading the Number in Context
External references
- U.S. FDA, guidance on research-use-only and investigational-use-only in-vitro diagnostic products.
- United States Pharmacopeia, general chapters on chromatographic purity and reference standards.
- Aggregated keyword-volume tooling, U.S. query data, Q1 to Q2 2026.
- Public corporate filings and WHOIS registration records for the 50 audited supplier domains.
- Internal BioFusion Research COA Rubric v1.0 scorecards, available on request.
Q3 2026 publishes in early August, against the same rubric.
Each edition is an independent audit of the U.S. research-peptide category, written for the bench and the procurement desk. Documentation is available on request for the compounds we carry.